| Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial RL Theriault, A Lipton, GN Hortobagyi, R Leff, S Glück, JF Stewart, ... Journal of Clinical Oncology 17 (3), 846-846, 1999 | 756 | 1999 |
| Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma: Results of two randomized trials designed for combined analysis J Bonneterre, A Buzdar, JMA Nabholtz, JFR Robertson, B Thürlimann, ... Cancer 92 (9), 2247-2258, 2001 | 717 | 2001 |
| How stress management improves quality of life after treatment for breast cancer. MH Antoni, SC Lechner, A Kazi, SR Wimberly, T Sifre, KR Urcuyo, ... Journal of consulting and clinical psychology 74 (6), 1143, 2006 | 460 | 2006 |
| Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes JA Russell, HT Tran, D Quinlan, A Chaudhry, P Duggan, C Brown, ... Biology of Blood and Marrow Transplantation 8 (9), 468-476, 2002 | 324 | 2002 |
| Molecular profiling for breast cancer: a comprehensive review M Kittaneh, AJ Montero, S Glück Biomarkers in cancer 5, BIC. S9455, 2013 | 260 | 2013 |
| TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine±trastuzumab S Glück, JS Ross, M Royce, EF McKenna, CM Perou, E Avisar, L Wu Breast cancer research and treatment 132, 781-791, 2012 | 242 | 2012 |
| Treating breast cancer in the 21st century: emerging biological therapies G Tinoco, S Warsch, S Glück, K Avancha, AJ Montero Journal of Cancer 4 (2), 117, 2013 | 219 | 2013 |
| Long‐term psychological benefits of cognitive‐behavioral stress management for women with breast cancer: 11‐year follow‐up of a randomized controlled trial JM Stagl, LC Bouchard, SC Lechner, BB Blomberg, LM Gudenkauf, ... Cancer 121 (11), 1873-1881, 2015 | 209 | 2015 |
| The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity R Syme, M Bewick, D Stewart, K Porter, T Chadderton, S Glück Biology of Blood and Marrow Transplantation 10 (2), 135-141, 2004 | 180 | 2004 |
| Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer KM Phillips, MH Antoni, SC Lechner, BB Blomberg, MM Llabre, E Avisar, ... Psychosomatic medicine 70 (9), 1044-1049, 2008 | 178 | 2008 |
| Molecularly targeted therapies for metastatic triple-negative breast cancer S Bayraktar, S Glück Breast cancer research and treatment 138, 21-35, 2013 | 176 | 2013 |
| Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2-Overexpressing Stage II or III … BP Coudert, R Largillier, L Arnould, P Chollet, M Campone, D Coeffic, ... Journal of clinical oncology 25 (19), 2678-2684, 2007 | 163 | 2007 |
| Participation in cancer clinical trials: why are patients not participating? MM Byrne, SL Tannenbaum, S Glück, J Hurley, M Antoni Medical Decision Making 34 (1), 116-126, 2014 | 152 | 2014 |
| High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma T Cheng, P Forsyth, A Chaudhry, D Morris, S Glück, JA Russell, ... Bone Marrow Transplantation 31 (8), 679-685, 2003 | 150 | 2003 |
| A randomized controlled trial of cognitive-behavioral stress management in breast cancer: survival and recurrence at 11-year follow-up JM Stagl, SC Lechner, CS Carver, LC Bouchard, LM Gudenkauf, ... Breast cancer research and treatment 154, 319-328, 2015 | 139 | 2015 |
| Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma DM Brizel, BA Murphy, DI Rosenthal, KJ Pandya, S Glück, HE Brizel, ... Journal of clinical oncology 26 (15), 2489-2496, 2008 | 137 | 2008 |
| Requirement for phospholipase C-γ1 enzymatic activity in growth factor-induced mitogenesis Z Wang, S Glück, L Zhang, MF Moran Molecular and cellular biology 18 (1), 590-597, 1998 | 132 | 1998 |
| Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy S Glück, F de Snoo, J Peeters, L Stork-Sloots, G Somlo Breast cancer research and treatment 139, 759-767, 2013 | 126 | 2013 |
| Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II … AJ Montero, CM Diaz-Montero, YE Deutsch, J Hurley, LG Koniaris, ... Breast cancer research and treatment 132, 215-223, 2012 | 120 | 2012 |
| nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results … DA Yardley, R Coleman, P Conte, J Cortes, A Brufsky, M Shtivelband, ... Annals of oncology 29 (8), 1763-1770, 2018 | 119 | 2018 |
Michael AntoniUniversity of MiamiVerified email at miami.edu
